| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01518283 | Hormone Refractory Prostate Cancer | Drug: Cabazitaxel 10 mg/m2 | Spanish Oncology Genito-Urinary Group | Phase 2 | 2012-05-01 | 2016-10-13 |
| NCT02512458 | Bone Metastatic Prostate Cancer | Drug: Cabazitaxel | Hellenic Cooperative Oncology Group|Sanofi | Phase 2 | 2015-07-01 | 2016-11-25 |
| NCT01830231 | Urothelium Transitional Cell Carcinoma | Drug: Cabazitaxel|Drug: Vinflunine | Associaci per a la Recerca Oncologica, Spain | Phase 2|Phase 3 | 2012-10-01 | 2014-01-27 |
| NCT01335204 | Prostate Cancer|Prostatic Neoplasms | Drug: Cabazitaxel plus bavituximab | Medical University of South Carolina|Peregrine Pharmaceuticals | Phase 1|Phase 2 | 2011-06-01 | 2013-03-20 |
| NCT03043989 | Prostate Cancer | Drug: Docetaxel|Drug: Cabazitaxel|Drug: Clarithromycin | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2017-02-15 | 2017-02-13 |
| NCT01650285 | Prostate Cancer | Drug: Cabazitaxel | Brown University | Phase 2 | 2013-01-01 | 2015-06-09 |
| NCT01254279 | Prostate Cancer Metastatic | Drug: CABAZITAXEL | Sanofi | Phase 3 | 2010-12-01 | 2015-01-19 |
| NCT02478502 | Testicular Cancer | Drug: cabazitaxel | Jan Oldenburg|Sanofi|University Hospital, Akershus | Phase 2 | 2015-06-01 | 2017-01-16 |
| NCT01740570 | Brain Cancer | Drug: Cabazitaxel | M.D. Anderson Cancer Center|Sanofi | Phase 1|Phase 2 | 2013-04-01 | 2013-03-07 |
| NCT01981668 | Prostatic Neoplasms | Drug: cabazitaxel | Nova Scotia Cancer Centre|Sanofi | Phase 1 | | 2014-03-18 |
| NCT02560337 | Ovarian Cancer | Drug: Cabazitaxel|Drug: Tocotrienol | Vejle Hospital | Phase 2 | 2015-09-01 | 2016-10-13 |
| NCT01845792 | Prostate Cancer | Drug: Cabazitaxel with Abiraterone Acetate|Drug: Cabazitaxel | University of Colorado, Denver|Janssen Services, LLC | Phase 2 | 2013-07-01 | 2017-03-06 |
| NCT02204332 | Colorectal Cancer | Drug: Cabazitaxel|Other: Best Supportive Care | Hospital Clinico Universitario de Santiago|Fundaci贸n Ramn Domnguez | Phase 2 | 2013-03-01 | 2014-07-29 |
| NCT01693549 | Breast Cancer | Drug: Cabazitaxel | Hellenic Cooperative Oncology Group|Sanofi | Phase 2 | 2012-09-01 | 2017-02-13 |
| NCT01941550 | High-Risk Cancer | Drug: Cabazitaxel chemotherapy | RWTH Aachen University | Phase 2 | 2013-07-01 | 2016-09-12 |
| NCT01913652 | Dedifferentiated Liposarcoma | Drug: Cabazitaxel|Drug: Prolonged infusional ifosfamide | European Organisation for Research and Treatment of Cancer - EORTC|Sanofi | Phase 2 | 2014-10-01 | 2016-10-11 |
| NCT01750866 | Castrate-resistant Metastatic Prostate Cancer | Drug: Cabazitaxel|Drug: Prednisone|Drug: Granulocyte colony-stimulating factor (G-CSF) | Case Comprehensive Cancer Center | Phase 2 | 2013-02-01 | 2013-10-15 |
| NCT01420250 | Prostate Cancer | Drug: Cabazitaxel|Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Anti-Androgen Therapy: Bicalutamide|Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist | Sidney Kimmel Cancer Center at Thomas Jefferson University|Sanofi|Thomas Jefferson University | Phase 1 | 2011-09-01 | 2016-10-19 |
| NCT01757171 | Gastric Adenocarcinoma|Gastroesophageal Adenocarcinoma|Distal Esophageal Adenocarcinoma | Drug: Cabazitaxel | Weill Medical College of Cornell University|Sanofi | Phase 2 | 2012-12-01 | 2017-02-28 |
| NCT01620242 | Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer | Drug: Cabazitaxel | UNICANCER | Phase 2 | 2012-04-01 | 2016-06-16 |
